Requires covered entities report to the department of health regarding certain 340B drug discounts and what percentage of patients benefit from such discounts.
This bill adds a new section to the Public Health Law requiring certain 340B covered entities to file annual transparency reports with the Department of Health beginning April 1, 2027. The reports must cover the prior year and break out 340B drug acquisition costs, payments received from insurers and patients, the number and share of prescriptions filled with 340B drugs, and the extent to which patients receive sliding-fee-scale discounts or charity care. The bill also requires reporting on operating costs tied to passing 340B savings through to patients, as well as payments to contract pharmacies, third-party administrators, and other vendors involved in 340B compliance and administration.
The reporting obligation applies separately to each covered entity and each offsite outpatient facility, and it requires certification by an officer of the covered entity. The Department of Health must then post the reports on a publicly accessible website. The bill defines key terms such as 340B drug, 340B profits, contract pharmacy, low-income patient, and covered entity, while expressly excluding federally qualified health centers from the definition of covered entity for this section. The act takes effect immediately, though the first reports are not due until 2027.
The bill’s main legal impact is to create a new state-level disclosure regime for participants in the federal 340B drug pricing program. It does not change the federal 340B program itself, but it would impose new reporting, certification, and public posting requirements on hospitals and other covered entities in New York that participate in the program, along with related pharmacies and administrators whose payments and roles must be disclosed. The measure is aimed at increasing transparency around whether 340B savings are being used to benefit patients, especially low-income patients, through reduced cost sharing, sliding fee scales, or charity care.
Because there are no committee transcripts or recorded votes provided, the available context does not show formal debate or recorded support/opposition. Based on the bill text and caption, the general tone appears oversight-oriented and consumer-protection focused, with an emphasis on accountability and patient benefit. The likely point of contention is whether the reporting requirements are too burdensome or intrusive for covered entities and their contract pharmacy arrangements, versus whether the disclosures are necessary to ensure that 340B discounts are actually reaching vulnerable patients rather than being absorbed as institutional revenue or administrative costs.
This bill would amend the Public Health Law by adding section 280-e, creating a new annual reporting and public disclosure requirement for certain 340B covered entities. It would require detailed reporting on drug acquisition costs, revenues, patient utilization, charity care, sliding-fee-scale use, contract pharmacy arrangements, and payments to third parties, with the Department of Health publishing the reports online. The practical effect is to increase state oversight and transparency for hospitals and other participating entities in the 340B program, while not altering the underlying federal drug discount program itself.
No votes or committee transcripts were provided, so there is no recorded legislative debate to measure directly. The bill’s framing suggests a generally favorable sentiment toward transparency, accountability, and patient protection, especially for low-income patients and charity care recipients. At the same time, the structure of the bill indicates an awareness that 340B program operations are complex and may involve significant administrative and pharmacy-related costs, which could draw concern from affected providers.
The main likely point of contention is the scope and burden of the reporting requirements. Covered entities, contract pharmacies, and third-party administrators may object that the bill requires detailed financial and operational disclosures, including remuneration and out-of-state pharmacy information, that could be administratively costly or sensitive. Supporters would likely argue that such transparency is needed to verify that 340B savings are benefiting patients through lower cost sharing, sliding fee scales, and charity care, rather than being retained by institutions or intermediaries. Another possible issue is the bill’s exclusion of federally qualified health centers from the definition of covered entity, which may be viewed as a policy choice that narrows the reporting mandate.